Overview
Dyne Therapeutics, Inc. is a U.S.-based, clinical-stage biotechnology company developing medicines for genetically driven neuromuscular diseases. Its stated mission is to deliver functional improvement for people living with these conditions. The company’s FORCE platform is designed to deliver therapeutic payloads, including oligonucleotides and enzymes, to muscle and the central nervous system. Its investigational pipeline includes programs for Duchenne muscular dystrophy, myotonic dystrophy type 1, facioscapulohumeral dystrophy and Pompe disease.[1][2][3][4]
Founded in 2017 and headquartered in Waltham, Massachusetts, Dyne conducts global clinical trials and pursues U.S. and ex-U.S. development pathways. As of June 30, 2026, it had no candidates approved for commercial sale, so it had no sales of approved products; the reviewed filing does not provide a total employee count.[5][6][7][8] [1][2][3][4][5][6][7][8]
Products & services
Dyne Therapeutics’ product candidates are investigational medicines built using its FORCE platform, which combines a transferrin-receptor-1-targeting antibody fragment with a therapeutic payload, such as an oligonucleotide or enzyme, to deliver it to muscle and the central nervous system.[1]
Its lead candidates include zeleciment rostudirsen (z-rostudirsen; DYNE-251), an exon-skipping therapy for Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping, designed to enable production of near-full-length dystrophin; and zeleciment basivarsen (z-basivarsen; DYNE-101), for myotonic dystrophy type 1, designed to reduce toxic DMPK RNA and restore normal mRNA processing. The company also has DYNE-253, DYNE-245, DYNE-244 and DYNE-255 in development for DMD amenable to exon skipping 53, 45, 44 and 55, respectively.[9][3][10]
Other candidates include DYNE-302 for facioscapulohumeral muscular dystrophy, which uses the FORCE platform and had entered planned Phase 1 development following IND clearance in July 2026, and DYNE-401 for Pompe disease, a FORCE-based enzyme-replacement approach designed to deliver GAA. Preclinical findings reported for DYNE-401 included glycogen clearance in muscle and CNS in a mouse model.[11][12][13][4]
Dyne reported no product-sales revenue and stated that it did not expect product revenue before at least 2027, if ever; it did not provide product-specific revenue or performance percentages.[14] [1][9][3][10][11][12][13][4][14]
Geographic presence
Dyne Therapeutics’ disclosed physical footprint is centered in Waltham, Massachusetts. Its principal executive offices and principal facilities are at 1560 Trapelo Road, where it leases approximately 68,000 square feet of office and laboratory space; the lease runs through March 2030, with two five-year extension options.[15][5][16]
The company does not own or operate manufacturing facilities and relies on third-party suppliers for manufacturing. Its latest report, for the quarter ended June 30, 2026, describes several clinical trials as global but does not specify participating countries in those disclosures.[17][6][18][19]
Dyne reported no revenue from product sales, so there is no current product-sales geography to report. The reviewed disclosures provide no employee distribution by country or region.[14] [15][5][16][17][6][18][19][14]
Business segments
Dyne Therapeutics reports one operating segment and one reportable segment. The company does not disclose separate segment contribution percentages; its filings report no product-sales revenue, so revenue shares by program are not available.[20][14]
Its programs provide an indication-based view of its activities, but are not reported segments: z-rostudirsen and other candidates address Duchenne muscular dystrophy; z-basivarsen addresses myotonic dystrophy type 1; DYNE-302 is being developed for facioscapulohumeral muscular dystrophy; and DYNE-401 targets Pompe disease. The company does not report revenue-contribution percentages for these programs.[9][3][10][21][4] [20][14][9][3][10][21][4]
Company history
Dyne Therapeutics was incorporated in Delaware on December 1, 2017. The company launched in April 2019 with a $50 million Series A financing, backed by investors including Atlas Venture, Forbion and MPM Capital.[22][23]
In 2020, Dyne announced a $115 million financing and completed its initial public offering in September, raising approximately $246 million in net proceeds.[24][25]
In 2022, the company began clinical testing of DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy. Dyne reported initial efficacy assessments in 2024; that March, John Cox became president and CEO, succeeding Joshua Brumm.[26][27][28][29]
In 2025, the FDA granted DYNE-251 Breakthrough Therapy Designation, and Dyne reported positive topline results from the DELIVER registrational-expansion study. In 2026, the company initiated the Phase 3 FORZETTO trial of z-rostudirsen; the FDA also accepted its biologics license application for review and granted Priority Review.[30][31][32][33] [22][23][24][25][26][27][28][29][30][31][32][33][22][23][24][26][27][29][30][31]
Sources
- Dyne Therapeutics, Inc. — Full financial report (2026 Q 2)
- Dyne Therapeutics, Inc. — Full financial report (2025 Y)[16]
- www.sec.gov[22]
- www.biospace.com[23]
- dynetx.gcs-web.com[24]
- Dyne Therapeutics, Inc. — Full financial report (2021 Y)[25]
- investors.dyne-tx.com[26]
- investors.dyne-tx.com[27]
- Dyne Therapeutics, Inc. — Full financial report (2023 Y)[28]
- www.sec.gov[29]
- investors.dyne-tx.com[30]
- investors.dyne-tx.com[31]
- Dyne Therapeutics, Inc. — Press release (2026 Q 2)[32][33]
Continue your research
From company context to financial detail.
Explore original sources and worldwide fundamental financial data and intelligence with Finbar.
Explore Dyne Therapeutics, Inc. in Finbar ↗